Shenzhen Hepalink Pharmaceutical Co Ltd (002399) - Net Assets

Latest as of December 2025: CN¥12.08 Billion CNY ≈ $1.77 Billion USD

Based on the latest financial reports, Shenzhen Hepalink Pharmaceutical Co Ltd (002399) has net assets worth CN¥12.08 Billion CNY (≈ $1.77 Billion USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥16.63 Billion ≈ $2.43 Billion USD) and total liabilities (CN¥4.55 Billion ≈ $666.04 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 002399 financial resilience to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥12.08 Billion
% of Total Assets 72.63%
Annual Growth Rate 29.32%
5-Year Change 4.83%
10-Year Change 49.35%
Growth Volatility 151.6

Shenzhen Hepalink Pharmaceutical Co Ltd - Net Assets Trend (2006–2025)

This chart illustrates how Shenzhen Hepalink Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore how large is Shenzhen Hepalink Pharmaceutical Co Ltd's balance sheet for the complete picture of this company's asset base.

Annual Net Assets for Shenzhen Hepalink Pharmaceutical Co Ltd (2006–2025)

The table below shows the annual net assets of Shenzhen Hepalink Pharmaceutical Co Ltd from 2006 to 2025. For live valuation and market cap data, see Shenzhen Hepalink Pharmaceutical Co Ltd market cap and net worth.

Year Net Assets Change
2025-12-31 CN¥12.08 Billion
≈ $1.77 Billion		 -1.00%
2024-12-31 CN¥12.20 Billion
≈ $1.79 Billion		 +1.78%
2023-12-31 CN¥11.99 Billion
≈ $1.75 Billion		 -3.38%
2022-12-31 CN¥12.41 Billion
≈ $1.82 Billion		 +7.67%
2021-12-31 CN¥11.52 Billion
≈ $1.69 Billion		 -1.42%
2020-12-31 CN¥11.69 Billion
≈ $1.71 Billion		 +56.46%
2019-12-31 CN¥7.47 Billion
≈ $1.09 Billion		 +19.64%
2018-12-31 CN¥6.24 Billion
≈ $913.80 Million		 -18.76%
2017-12-31 CN¥7.69 Billion
≈ $1.12 Billion		 -4.97%
2016-12-31 CN¥8.09 Billion
≈ $1.18 Billion		 -8.01%
2015-12-31 CN¥8.79 Billion
≈ $1.29 Billion		 +5.27%
2014-12-31 CN¥8.35 Billion
≈ $1.22 Billion		 +3.53%
2013-12-31 CN¥8.07 Billion
≈ $1.18 Billion		 +0.28%
2012-12-31 CN¥8.05 Billion
≈ $1.18 Billion		 +1.66%
2011-12-31 CN¥7.91 Billion
≈ $1.16 Billion		 -1.36%
2010-12-31 CN¥8.02 Billion
≈ $1.17 Billion		 +649.66%
2009-12-31 CN¥1.07 Billion
≈ $156.62 Million		 +247.68%
2008-12-31 CN¥307.83 Million
≈ $45.05 Million		 +110.21%
2007-12-31 CN¥146.44 Million
≈ $21.43 Million		 +60.34%
2006-12-31 CN¥91.33 Million
≈ $13.36 Million		 --

Equity Component Analysis

This analysis shows how different components contribute to Shenzhen Hepalink Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 10448.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Retained Earnings CN¥4.02 Billion 33.42%
Other Components CN¥8.01 Billion 66.58%
Total Equity CN¥12.03 Billion 100.00%

Shenzhen Hepalink Pharmaceutical Co Ltd Competitors by Market Cap

The table below lists competitors of Shenzhen Hepalink Pharmaceutical Co Ltd ranked by their market capitalization.

Company Market Cap
Shanghai Jahwa United Co Ltd
SHG:600315
 $1.98 Billion
ACME Solar Holdings Limited
NSE:ACMESOLAR
 $1.98 Billion
Ourpalm
SHE:300315
 $1.99 Billion
STROEER (UNSP.ARD)/4/1
F:SAXB
 $1.99 Billion
Austevoll Seafood ASA
OL:AUSS
 $1.98 Billion
Xinhuanet Co Ltd
SHG:603888
 $1.98 Billion
Craftsman Automation Limited
NSE:CRAFTSMAN
 $1.98 Billion
East Group Co Ltd
SHE:300376
 $1.98 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Shenzhen Hepalink Pharmaceutical Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 12,148,672,778 to 12,030,940,527, a change of -117,732,251 (-1.0%).
  • Net income of 349,485,812 contributed positively to equity growth.
  • Dividend payments of 430,809,733 reduced retained earnings.
  • Other comprehensive income decreased equity by 962,559,199.
  • Other factors increased equity by 926,150,870.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income CN¥349.49 Million +2.9%
Dividends Paid CN¥430.81 Million -3.58%
Other Comprehensive Income CN¥-962.56 Million -8.0%
Other Changes CN¥926.15 Million +7.7%
Total Change CN¥- -0.97%

Book Value vs Market Value Analysis

This analysis compares Shenzhen Hepalink Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1.33x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 34.34x to 1.33x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2006-12-31 CN¥0.32 CN¥10.87 x
2007-12-31 CN¥0.51 CN¥10.87 x
2008-12-31 CN¥1.07 CN¥10.87 x
2009-12-31 CN¥0.93 CN¥10.87 x
2010-12-31 CN¥12.93 CN¥10.87 x
2011-12-31 CN¥6.13 CN¥10.87 x
2012-12-31 CN¥6.22 CN¥10.87 x
2013-12-31 CN¥6.24 CN¥10.87 x
2014-12-31 CN¥6.46 CN¥10.87 x
2015-12-31 CN¥6.88 CN¥10.87 x
2016-12-31 CN¥6.36 CN¥10.87 x
2017-12-31 CN¥6.08 CN¥10.87 x
2018-12-31 CN¥4.87 CN¥10.87 x
2019-12-31 CN¥5.89 CN¥10.87 x
2020-12-31 CN¥8.55 CN¥10.87 x
2021-12-31 CN¥7.78 CN¥10.87 x
2022-12-31 CN¥8.39 CN¥10.87 x
2023-12-31 CN¥8.06 CN¥10.87 x
2024-12-31 CN¥8.27 CN¥10.87 x
2025-12-31 CN¥8.20 CN¥10.87 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Shenzhen Hepalink Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 2.90%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 6.38%
  • • Asset Turnover: 0.33x
  • • Equity Multiplier: 1.38x
  • Recent ROE (2.90%) is below the historical average (16.16%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2006 52.43% 17.24% 0.80x 3.82x CN¥38.75 Million
2007 46.55% 22.77% 1.16x 1.76x CN¥53.52 Million
2008 52.43% 37.08% 0.75x 1.88x CN¥130.61 Million
2009 75.98% 36.38% 1.62x 1.29x CN¥702.57 Million
2010 15.13% 31.39% 0.47x 1.02x CN¥410.32 Million
2011 7.96% 24.94% 0.31x 1.02x CN¥-159.56 Million
2012 7.84% 35.44% 0.21x 1.04x CN¥-171.76 Million
2013 3.97% 20.97% 0.18x 1.04x CN¥-481.27 Million
2014 4.09% 17.27% 0.20x 1.20x CN¥-488.70 Million
2015 6.65% 25.29% 0.19x 1.40x CN¥-292.13 Million
2016 4.98% 17.55% 0.18x 1.62x CN¥-400.23 Million
2017 2.59% 6.92% 0.22x 1.74x CN¥-561.38 Million
2018 9.75% 12.28% 0.35x 2.25x CN¥-15.34 Million
2019 14.42% 22.91% 0.30x 2.07x CN¥324.65 Million
2020 8.85% 19.21% 0.28x 1.64x CN¥-132.73 Million
2021 2.11% 3.78% 0.33x 1.67x CN¥-900.35 Million
2022 5.91% 10.16% 0.34x 1.69x CN¥-503.67 Million
2023 -6.57% -14.42% 0.28x 1.61x CN¥-1.97 Billion
2024 5.32% 12.30% 0.30x 1.43x CN¥-568.13 Million
2025 2.90% 6.38% 0.33x 1.38x CN¥-853.61 Million

Industry Comparison

This section compares Shenzhen Hepalink Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $1,347,197,696
  • Average return on equity (ROE) among peers: 4.46%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Shenzhen Hepalink Pharmaceutical Co Ltd (002399) CN¥12.08 Billion 52.43% 0.38x $1.98 Billion
Shenzhen Neptunus Bioengineering Co Ltd (000078) $2.84 Billion -41.97% 9.13x $1.22 Billion
Anhui Fengyuan Pharmaceutical Co Ltd (000153) $638.89 Million 0.88% 0.70x $438.59 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423) $1.05 Billion 10.46% 0.19x $5.18 Billion
Livzon Pharmaceutical Group Inc (000513) $1.07 Billion 3.83% 0.46x $2.81 Billion
Wedge Industrial Co Ltd (000534) $1.29 Billion 11.69% 1.47x $2.95 Billion
Yunnan Baiyao Group Co Ltd (000538) $35.11 Million 18.13% 0.80x $13.85 Billion
Hainan Haiyao Co Ltd (000566) $5.08 Billion 1.71% 1.08x $949.23 Million
Tus Pharmaceutical Group Co Ltd (000590) $141.91 Million 11.01% 0.32x $391.07 Million
Northeast Pharmaceutical Group Co Ltd (000597) $994.58 Million 2.01% 2.11x $1.03 Billion
Jilin Aodong Pharmaceutical Group Co Ltd (000623) $332.48 Million 26.89% 0.68x $3.30 Billion

About Shenzhen Hepalink Pharmaceutical Co Ltd

SHE:002399 China Drug Manufacturers - Specialty & Generic
Market Cap
$1.98 Billion
CN¥13.56 Billion CNY
Market Cap Rank
#6301 Global
#1396 in China
Share Price
CN¥10.87
Change (1 day)
+0.93%
52-Week Range
CN¥10.33 - CN¥13.88
All Time High
CN¥28.69
Categories
Companies in China Drug Manufacturers - Specialty & Generic
About

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. provides pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. It operates in four segments: Finished Dose Pharmaceutical Products, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization (CDMO), and Others. The company offers finished dose pharmaceutical products,… Read more